LKC Technologies hosted an exclusive panel discussion featuring world-renowned researchers and experts in ophthalmology, optic neuropathy, and psychiatric disorders during ARVO 2017. LKC Technologies’ Dr. Quentin Davis, Ph.D., led the discussion with Dr. Randy Kardon M.D. Ph.D. (University of Iowa, USA), Dr. Omar Mahroo (Moorfields Eye Hospital and St Thomas’ Hospital, London, UK), and Dr. Steven Silverstein, Ph.D. (Rutgers University, USA). Each expert in their field presented some of the most innovative research studies from around the world utilizing flash and flicker ERG testing.
Panelists discovered and discussed:
- What’s new in electrophysiology research
- Effects of pupillary response with ERGs
- Review of Photopic Negative Response (PhNR) testing in regards to pupil-light reflex and optic neuropathies
- Heritability study of identical and fraternal twins to identify the genetic contribution to inter-person variability in ERG responses
- The future of ERG research for various diseases including diabetic retinopathy, Birdshot uveitis, and mental health disorders such as schizophrenia
VIEW THE VIDEOS
Dr. Randy Kardon – Reduction of the Photopic Negative Response of Retinal Ganglion Cells in Optic Neuropathy: Assessment Using a New Portable Handheld Device
Dr. Omar Mahroo – Studies in the TwinsUK cohort on heritability, preliminary studies on Birdshot uveitis, Autism spectrum disorder, and ABCA4 retinopathy (Stargardt)
Dr. Steven Silverstein – Flash Electroretinogram (fERG) Findings in schizophrenia
Dr. Quentin Davis – Overview on the RETeval device capabilities
ABOUT THE SPEAKERS
Dr. Quentin Davis, Ph.D. (Moderator)
Quentin is Vice President of Operations and Development responsible for the technical aspects for the company’s UTAS and RETeval® products. Quentin was previously involved in immunoassay, biological warfare detection, and in vitro diagnostic device development for 13 years before joining LKC in 2010. At LKC, he was the lead designer for the RETeval device and was a key member of the team that ran the 468 subject clinical trial on detecting diabetic retinopathy. His current focus is translating cutting-edge ERG research into clinically useful tools. Quentin is a published author and frequent presenter on various topics related to electrophysiology. He is a registered U.S. Patent Agent and is an inventor on 19 U.S. patent applications. Quentin holds BS, MS, and Ph.D. degrees from the Massachusetts Institute of Technology in Electrical Engineering and Computer Science.
Dr . Randy Kardon M.D. Ph.D. (University of Iowa, USA)
Randy Kardon M.D. Ph.D., is tenured Professor of Ophthalmology and Director of the Neuro-ophthalmology Service at the University of Iowa and Veterans Administration Hospitals. He holds the Pomerantz Family Chair in Ophthalmology and is Director of the Iowa City Veterans Administration Center for the Prevention and Treatment of Visual Loss. Dr. Kardon has published over 20 chapters, co-authored a textbook, and has published over 200 peer-reviewed journal articles. Dr. Kardon is presently the Principal Investigator or co-PI on 8 major grants externally funded by the Veterans Administration, NIH, and the Department of Defense, including funding as part of the Chronic Effects of Neurotrauma Consortium (CENC) for a prospective study entitled “Visual Sensory Impairments and Progression Following Mild Traumatic Brain Injury”. He has been funded for his research from the Department of Veterans Affairs since 1990, and was one of the first ophthalmologists to receive a VA Career Development Award. He did most all of his training (undergraduate, combined M.D.-Ph.D, residency and two year fellowship in neuro-ophthalmology at the University of Iowa, Iowa City, Iowa, USA, and started as faculty in Ophthalmology in 1989. Dr. Kardon currently teaches and mentors undergraduate students, medical students, and residents and has received a University of Iowa Collegiate Teaching Award for his teaching and commitment to education. He currently serves on the editorial board for the Journal of Neuro-ophthalmology. His main areas of current research interest include use of facial features to diagnose and monitor eye and neurological disorders, pupil physiology and its clinical application, diagnosis and treatment of light sensitivity, traumatic brain injury and its treatment, therapeutic interventions for preserving vision in blinding eye diseases, and investigating structure-function relationships in the visual system using optical coherence tomography (OCT), ocular blood flow, image analysis, and MRI. Dr. Kardon is actively involved in the development of telemedicine tools for objectively evaluating the status of the visual and neurological systems for testing in remote locations. He is cofounder of MedFace and FaceX, start-up companies that are developing low cost mobile devices for precise video assessment of facial responses to light stimuli to diagnose and monitor treatment of medical, neurological and eye disorders.
Dr. Omar Mahroo (Kings College, London, UK)
Dr. Mahroo is a retinal specialist working at Moorfields Eye Hospital and at St Thomas’ Hospital in London. His undergraduate degree, clinical medical degree and PhD were at the University of Cambridge, and his post-doctoral work was at Cambridge and at the Australian National University. He completed his ophthalmology training in London, and is a Fellow of the Royal College of Ophthalmologists. His research, now based at King’s College London and University College London, explores retinal function, particularly the application of retinal electrophysiology to advance our understanding of retinal mechanisms in health and disease.
Dr. Steven Silverstein, Ph.D. (Rutgers University, USA)
Dr. Steven Silverstein is Director of Research, and Director of the Division of Schizophrenia Research at Rutgers University Behavioral Health Care (UBHC), the Co-Director of the Rutgers-Princeton Center for Computational Cognitive Neuropsychiatry, and Professor of Psychiatry at Rutgers – Robert Wood Johnson Medical School. He is the former Chair of the American Psychological Association’s Task Force on Serious Mental Illness, and the current President of the Society for Research in Psychopathology. Dr. Silverstein received his Ph.D. in Psychology from the State University of New York at Buffalo in 1989, and completed his internship and fellowship at Cornell Medical College from 1988-1990. He has been at Rutgers since 2006 and since 2008 he has been Director of Research for UBHC. Dr. Silverstein has over 25 years of experience in treating people with schizophrenia and bipolar disorder, and has directed inpatient units and outpatient programs for these populations. Dr. Silverstein’s research interests are in the development of schizophrenia, perceptual and cognitive changes found in schizophrenia, and prediction of treatment response and relapse. He has over 200 publications related to schizophrenia, and is currently Principal Investigator (PI) or site PI on multiple (n=10) NIMH, state or foundation grants involving assessment and treatment. Dr. Silverstein is the recipient of many awards, including the United States Psychiatric Rehabilitation Association’s Armin Loeb Award for Research in Psychiatric Rehabilitation in 2008, The New Jersey Psychological Associations Distinguished Researcher Award in 2009, the American Psychological Foundation’s Alexander Gralnick Research Investigator Prize in 2010, and the Trailblazer Award from the Schizophrenia Special Interest Group of the Society for Advancement of Behavioral and Cognitive Therapy in 2016.